Antineoplastic evaluation of novel 3,5-bis(benzylidene)-4-piperidones

The supervisors and their colleagues have discovered a number of compounds which have greater toxicity towards different tumours than normal cells. The first step in the proposal is to determine the maximum tolerated dose of the compounds in mice after which the candidate anticancer agents will be administered to a special breed of mice in which a human colon cancer has been implanted. We hope to find if the tumour will have been destroyed or reduced in size. In addition, experiments are scheduled to determine if the compounds prevent the colon tumour migrating (i.e. metastasizing) to other organs of the mice. Bertech requires novel anticancer agents in order to attach antibodies to them which are specific for colon cancers. In other words, this application is part of a long term strategy of Bertech to provide therapeutics and diagnostics for patients with colon cancer.

Faculty Supervisor:

J. R. Dimmock

Student:

Partner:

Bertech Pharma Ltd

Discipline:

Life Sciences

Sector:

Professional, scientific and technical services

University:

University of Saskatchewan

Program: